Drug reference
Adjunct or alternative treatment in hyperlipidaemias of types IIb and IV in patients who have not responded adequately to other lipid-regulating drugs such as a statin or fibrate, and lifestyle changes (including diet, exercise, and weight reduction) ▶BY MOUTH ▶Adult: 250 mg 2–3 times a day
PDF page 235
Peptic ulcer
PDF page 235
▶Common or very common Asthenia. gastrointestinal discomfort. headache. skin reactions. vasodilation ▶Uncommon Angioedema. arthralgia. feeling hot. malaise. myalgia. myositis. nausea ▶Frequency not known Bronchospasm. diarrhoea. dry eye. eye disorder. eyes gritty
PDF page 235
Manufacturer advises avoid—no information available.
PDF page 235
Manufacturer advises avoid—no information available.
PDF page 235
Avoid if eGFR less than 30 mL/minute/1.73 m2. Dose adjustments Reduce dose to 250 mg 1–2 times daily if eGFR 30–60 mL/minute/1.73 m2.
PDF page 235
Monitor hepatic and renal function.
PDF page 235
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 21 ▶Olbetam (Pfizer Ltd) Acipimox 250 mg Olbetam 250mg capsules | 90 capsule P £46.33 DT = £46.33
PDF page 235
250 mg 2–3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 235
